Futilimab
Futilimab is a monoclonal antibody indicated in the treatment of metastatic cancer complicated by septic shock, multi-organ system failure, and death.[1] The drug costs about $4,000,000,000 per infusion, is infused rectally over 35 days, and extends life-expectancy by an average of 3 minutes. When used with hospicillin, the effects of futilimab are synergistic.
Related Topics
References
|
Fun Stuff
|